Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by V501

Research Leaders

5 sponsors active, led by Merck Sharp & Dohme LLC

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 6 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

5Total
Phase 1 (1)
Phase 1/2 (1)
Phase 2 (1)
Phase 3 (2)

Trial Status

Completed5
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 5 completed trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07234838Recruiting

Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)

NCT01796821Phase 2CompletedPrimary

Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)

NCT02576054Phase 3Completed

Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

NCT01862874Phase 3Completed

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

NCT01555112Phase 1/2Completed

Safety and Efficacy Study to Test Topical AS101 for External Genital Warts

NCT00002327Phase 1Completed

The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients

Showing all 6 trials

Research Network

Common Treatments

  • V5012
  • Topical As1011
  • Vehicle Gel1
  • Srt100 Gel With 10 Sm1
  • Srt100 Gel With 23 Sm1

Active Sponsors

  • Merck Sharp & Dohme LLC2
  • Gilead Sciences1
  • Jonathan Krygier1
  • BioMAS Ltd1
  • G&E Herbal Biotechnology Co., LTD1

Top Investigators

Related Conditions

  • Anogenital Human Papilloma Virus Infection2
  • Psoriasis1
  • Condylomata Acuminata1
  • Biotherapies1
  • Hiv Infections1

Activity Timeline